Business
GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market
ATLANTA, GA, June 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies
About this update from Geovax Labs, Inc.
[{"type":"text","content":"ATLANTA, GA, June 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, is pleased to announce that it has been approved to trade on the OTCQB Venture Market as of June 4, 2020. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company at www.otcmarkets.com.\n \"I would like to thank our shareholders for their support as GeoVax worked toward this important milestone,\" stated David Dodd, President & CEO of GeoVax. \"Joining the OTCQB elevates our profile within the investment community, which we anticipate will help improve liquidity and broaden our shareholder base. We are excited for the future of GeoVax and look forward to the successful advancement of our vaccine development programs.\" The OTCQB Venture Market, operated by OTC Markets Group Inc., is a premier market for early-stage and developing companies. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a baseline for financial transparency and provide more comprehensive compliance requirements. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel proprietary vaccine platform (GV-MVA-VLP™). On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine (in vivo). The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The GV-MVA-VLP™ derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while typically providing the safety characteristics of a replication-defective vector. GeoVax’s current development programs are focused on preventive vaccines ...